Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG 3350 vs PEG 4000 for Constipation
NCT02292459Phase 3Withdrawn
- Sponsor
- Bayer
- Start
- Dec 2015
- Primary completion
- Dec 2015
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Biodegradable Polymers
01
Overview
Phase 3, randomised, open-label trial of polyethylene glycol 3350 in functional constipation (FC) (2 arms), sponsored by Bayer. Primary endpoint: Number of bowel movements per week at 7 days. Planned start Dec 2015; status: withdrawn.
02
Drugs
polyethylene glycol 3350
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on NCT02292459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292459.